News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,883 Results
Type
Article (14919)
Company Profile (299)
Press Release (266659)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79839)
Career Advice (163)
Deals (13337)
Drug Delivery (39)
Drug Development (50705)
Employer Resources (31)
FDA (5839)
Job Trends (5170)
News (145091)
Policy (10072)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (85)
Alliances (21761)
ALS (126)
Alzheimer's disease (1035)
Antibody-drug conjugate (ADC) (244)
Approvals (6035)
Artificial intelligence (267)
Autoimmune disease (119)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (101)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (348)
Cancer (3163)
Cardiovascular disease (239)
Career advice (148)
Career pathing (8)
CAR-T (224)
CDC (5)
Cell therapy (577)
Cervical cancer (14)
Clinical research (43723)
Collaboration (1168)
Company closure (2)
Compensation (603)
Complete response letters (41)
COVID-19 (1101)
CRISPR (88)
C-suite (565)
Cystic fibrosis (112)
Data (4359)
Denatured (15)
Depression (93)
Diabetes (256)
Diagnostics (1383)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (196)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31686)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51711)
Executive appointments (628)
FDA (7606)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (991)
Gene editing (185)
Generative AI (22)
Gene therapy (497)
GLP-1 (507)
Government (1149)
Grass and pollen (3)
Guidances (166)
Healthcare (6612)
HIV (18)
Huntington's disease (43)
IgA nephropathy (75)
Immunology and inflammation (194)
Immuno-oncology (43)
Indications (71)
Infectious disease (1211)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7346)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (243)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (425)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (380)
MASH (132)
Medical device (2666)
Medtech (2675)
Mergers & acquisitions (6623)
Metabolic disorders (733)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1965)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (867)
Now hiring (32)
Obesity (333)
Opinion (125)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (165)
Parkinson's disease (232)
Partnered (12)
Patents (306)
Patient recruitment (345)
Peanut (44)
People (26688)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15492)
Phase 2 (20315)
Phase 3 (12831)
Pipeline (3354)
Policy (91)
Postmarket research (853)
Preclinical (6540)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (661)
Real estate (1448)
Recruiting (12)
Regulatory (9922)
Reports (19)
Research institute (973)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (184)
Series B (140)
Service/supplier (1)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (340)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (53)
Last 7 days (315)
Last 30 days (1170)
Last 365 days (17848)
2026 (1965)
2025 (18098)
2024 (20544)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7485)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18274)
Australia (3114)
California (7141)
Canada (1857)
China (784)
Colorado (249)
Connecticut (255)
Delaware (237)
Europe (39211)
Florida (912)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (398)
India (36)
Indiana (162)
Iowa (8)
Japan (228)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (740)
Massachusetts (5629)
Michigan (110)
Minnesota (250)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1658)
New Mexico (13)
New York (1775)
North Carolina (837)
North Dakota (6)
Northern California (3516)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1287)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2831)
Tennessee (40)
Texas (921)
United States (23536)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (46)
281,883 Results for "corcept therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
January 26, 2026
·
2 min read
·
Tristan Manalac
Complete response letters
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
Corcept’s relacorilant was rejected for hypercortisolism late last year—a decision which CEO Joseph Belanoff expressed surprise with at the time.
February 2, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
January 23, 2026
·
7 min read
Complete response letters
FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices
Both companies received agency requests for more evidence of the effectiveness of their therapies.
January 2, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
January 1, 2026
·
3 min read
Press Releases
Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics
October 2, 2025
·
2 min read
Press Releases
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 28, 2025
·
1 min read
Press Releases
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
November 4, 2025
·
14 min read
ALS
Corcept Claims Survival Benefit in ALS Despite Missed Endpoint
Analysts at Truist Securities called the mid-stage data a “mixed bag,” also flagging gastrointestinal adverse events. However, the readout is unlikely to be “incremental” to Corcept’s overall stock narrative.
June 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
September 11, 2025
·
4 min read
1 of 28,189
Next
